Metabolomic biomarkers of psychotic conversion in ultra-high-risk subjects: a pilot study
Por:
Avella MT, Bertho G, Giraud N, Kébir O, Caradeuc C, Labad J, Papiol S, Schulze TG, Krebs MO, Chaumette B and Frajerman A
Publicada:
15 nov 2025
Ahead of Print:
15 nov 2025
Resumen:
Psychosis is a psychiatric condition that can become a chronic and severe psychiatric disorder affecting more than 1% of the population. The ultra-high risk (UHR) patients have a transition rate to psychosis of 25% after three years. We aimed to identify circulating metabolomic biomarkers for psychotic conversion in UHR patients using nuclear magnetic resonance (NMR) spectroscopy. We used samples from 35 UHR patients: 14 converters (UHR-C) and 21 non-converters (UHR-NC) at inclusion from the ICAAR cohort. Serum samples were analysed using the high-throughput screening IVDr NMR method. R and SIMCA were used for statistical analysis. Several lipoprotein parameters related to HDL and LDL metabolism were downregulated in UHR-C compared to UHR-NC at the time of inclusion. The 3 best lipoproteins to predict psychotic conversion at baseline were H4A1, H4FC, and L4FC (Area under the Curve (AUC) values were 0.81, 0.81, and 0.78, respectively). These lipoproteins were also negatively correlated with PANSS scores. Our study is the first to use NMR technology to identify biomarkers to predict the risk of psychotic transition in UHR subjects. This pilot study found lipoprotein parameters related to ApoA-1 and HDL-cholesterol (subclass 4) as potential biomarkers. These results need to be replicated on a larger sample. This study highlights the importance of the detailed analysis of circulant lipoproteins related to the brain using NMR technology in early psychosis to identify biomarkers of psychotic transitions and perhaps to better understand the physiopathology of psychosis.
Filiaciones:
Avella MT:
Institute of Psychiatry and Neurosciences of Paris, INSERM UMR 1266, Pathophysiology of Psychiatric Diseases, Université Paris Cité, Paris, France
Institute of Psychiatry, GDR 3557 of Psychiatry, GHU Paris, Paris, France
Bertho G:
Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris Cité, Paris, France
MetaboParis-Santé, UMS BioMedTech Facilities - Inserm US36 | CNRS UAR2009 | Université Paris Cité, Paris, France
Giraud N:
Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris Cité, Paris, France
MetaboParis-Santé, UMS BioMedTech Facilities - Inserm US36 | CNRS UAR2009 | Université Paris Cité, Paris, France
Kébir O:
Institute of Psychiatry and Neurosciences of Paris, INSERM UMR 1266, Pathophysiology of Psychiatric Diseases, Université Paris Cité, Paris, France
Institute of Psychiatry, GDR 3557 of Psychiatry, GHU Paris, Paris, France
Caradeuc C:
Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris Cité, Paris, France
MetaboParis-Santé, UMS BioMedTech Facilities - Inserm US36 | CNRS UAR2009 | Université Paris Cité, Paris, France
:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Mataro, Spain
Translational Neuroscience Research Unit I3PT-INc-UAB, Institut de Innovacio Investigacio Parc Tauli (I3PT), Institut de Neurociències, Universitat Autònoma de Barcelona, Sabadell, Spain
Centro de Investigacio Biomedica en Red deSalud Mental (CIBERSAM), Madrid, Spain
Papiol S:
Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, Munich, BY, Germany
Max Planck Institute of Psychiatry, Munich, Germany
Schulze TG:
Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, Munich, BY, Germany
Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA
Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University, Baltimore, MD, USA
Krebs MO:
Institute of Psychiatry and Neurosciences of Paris, INSERM UMR 1266, Pathophysiology of Psychiatric Diseases, Université Paris Cité, Paris, France
Institute of Psychiatry, GDR 3557 of Psychiatry, GHU Paris, Paris, France
PEPIT, GHU Paris Psychiatrie et Neurosciences, Paris, France
Chaumette B:
Institute of Psychiatry and Neurosciences of Paris, INSERM UMR 1266, Pathophysiology of Psychiatric Diseases, Université Paris Cité, Paris, France
Institute of Psychiatry, GDR 3557 of Psychiatry, GHU Paris, Paris, France
PEPIT, GHU Paris Psychiatrie et Neurosciences, Paris, France
Department of Psychiatry, McGill University, Montreal, Canada
Frajerman A:
Institute of Psychiatry and Neurosciences of Paris, INSERM UMR 1266, Pathophysiology of Psychiatric Diseases, Université Paris Cité, Paris, France
Institute of Psychiatry, GDR 3557 of Psychiatry, GHU Paris, Paris, France
Green Submitted, gold
|